MK-677 Dosage Guide: Ibutamoren Protocol, Timing & Cycle Length (2026)

MK-677 (ibutamoren, also designated MK-0677 and L-163,191) is a non-peptide, orally active ghrelin receptor agonist and growth hormone secretagogue. Unlike injectable GHRPs such as ipamorelin or GHRP-6 — see our peptides vs HGH comparison — MK-677 is a small molecule that mimics the action of ghrelin at the GHS-R1a receptor, stimulating pulsatile GH release and sustained IGF-1 elevation. Its oral bioavailability and 24-hour half-life make it unique among GH secretagogues — a single daily oral dose produces consistent, measurable GH and IGF-1 elevation, and no injection is required. MK-677 has been studied in published clinical trials for GH deficiency, muscle wasting, osteoporosis, and Alzheimer's disease, giving it an unusually robust human clinical data set — helping it rank high among growth hormone peptides. Getting the mk-677 dosage right matters more than people realize: as our MK-677 safety review details, the difference between 10 mg and 25 mg produces markedly different side effect profiles while offering diminishing incremental IGF-1 benefit.

Quick Answer: MK-677 Dosage at a Glance
Typical research dose: 10–25 mg per day
Frequency: Once daily (oral)
Route: Oral (no injection required)
Cycle length: 8–16 weeks
Half-life: ~24 hours
Best time to dose: Before bed (aligns with natural GH pulse)

MK-677 Dosage Chart

MK-677 Dosage Chart — Quick Reference

This mk-677 dosage chart summarizes the three main protocol tiers used in research. Most people start at the beginner level and assess tolerance before moving up. The sweet spot for most goals is 15–20 mg — enough to drive meaningful IGF-1 elevation without the aggressive hunger and water retention that comes with 25 mg.

Level	Daily Dose	Timing	Cycle Length	Off Period	Best For
Beginner	10 mg/day	Before bed	8–12 weeks	4 weeks	First cycle, women, anti-aging, sleep
Standard	15–20 mg/day	Before bed	8–12 weeks	4–6 weeks	Body recomp, general GH optimization
Advanced	25 mg/day	Before bed	8–12 weeks	6–8 weeks	Muscle growth, maximum IGF-1 elevation

Note that 50 mg/day has been studied in clinical trials for muscle wasting and cachexia — but the side effect burden at that level (significant hunger, edema, insulin resistance) makes it impractical for most research applications. The ibutamoren dosage sweet spot is clearly in the 10–25 mg range, and the chart above reflects that.

Standard MK-677 Dosage Protocols

MK-677's clinical trial data provides unusually clear dosing guidance relative to most research peptides. Multiple published studies have used 10 mg, 25 mg, and 50 mg daily doses, with 25 mg being the most widely studied dose for GH/IGF-1 optimization:

Protocol Tier	Daily Dose	IGF-1 Response	Best Suited For
Low-dose	10 mg/day	~40–52% IGF-1 increase (clinical data)	Tolerance assessment, elderly models, minimizing side effects
Standard	25 mg/day	~60–79% IGF-1 increase (clinical data)	GH optimization, body composition, bone density research
High-dose	50 mg/day	~70–80% IGF-1 increase (marginal gain over 25 mg)	Muscle wasting/cachexia models only; significantly increased side effects

The data from published trials (including those by Murphy et al. and Nass et al.) consistently show that 25 mg provides most of the IGF-1 benefit of 50 mg with substantially fewer side effects. The 10 mg dose is well-tolerated but produces more modest GH/IGF-1 responses. For most body composition and anti-aging research applications, 25 mg/day is the reference mk-677 dose.

Important distinction: MK-677 is not a peptide — it is a non-peptide small molecule that mimics peptide action at the ghrelin receptor. Unlike injectable GHRPs, it does not require reconstitution, syringes, or cold storage. It is typically supplied as oral capsules or a liquid solution for research purposes — see our guide to buying MK-677 for sourcing tips.

MK-677 Dosage for Women

The standard ibutamoren dosage literature is largely built on male research subjects, which means women are left guessing. Based on the available data and the compound's mechanism, the guidance is fairly straightforward: 10 mg/day is the right starting mk-677 dosage for women, and many find that's enough.

The key issue is that two of MK-677's main side effects — increased appetite and water retention — tend to be more pronounced in women at higher doses. Ghrelin receptor sensitivity may differ between sexes, and the hunger stimulation at 25 mg can be substantial enough to undermine body composition goals entirely. Water retention in the face and extremities is also more commonly reported by women at doses above 10 mg.

10 mg/day: Sweet spot for most women — delivers meaningful IGF-1 elevation (~40–52%), supports sleep quality, skin, and lean mass without overwhelming hunger
15 mg/day: Some women tolerate this well; assess hunger and water retention carefully before increasing from 10 mg
25 mg/day: Generally not recommended for women as a starting point — the side effect burden is significantly higher relative to the incremental benefit

For women focused on anti-aging, sleep quality, or skin health, the 10 mg mk-677 dosage is fully sufficient. There's no need to push higher unless a specific body composition goal demands it and tolerance at 10 mg has been established over several weeks.

MK-677 Dosage for Muscle Growth

If the primary goal is body recomposition — gaining lean mass and reducing fat — the mk-677 dosage needs to be in the 20–25 mg range to maximally elevate GH and IGF-1. This is where the compound earns its reputation — see our full MK-677 benefits and results breakdown. At 25 mg/day, published clinical trials have documented IGF-1 increases of 60–79% above baseline, sustained over months. That's a meaningful anabolic signal, particularly when combined with resistance training.

A few things to understand about MK-677 for muscle growth specifically:

GH/IGF-1 elevation alone doesn't build muscle. MK-677 creates the hormonal environment for growth, but resistance training is required to direct that signal toward lean mass rather than just fat mobilization. Studies on MK-677 in sedentary elderly subjects showed fat-free mass increases even without exercise — but the response in trained individuals with progressive overload is substantially greater.
The 25 mg mk-677 dose is the reference. Going to 50 mg produces only marginal additional IGF-1 elevation (~70–80% vs. 60–79%) with significantly more side effects. It's not worth it for muscle-building research.
Allow 4–6 weeks for measurable changes. MK-677 works through GH pulse amplification — it's not a rapid responder like creatine. Body composition changes typically become apparent at the 6–8 week mark.
Hunger management is critical. At 25 mg, appetite increases are significant. Unmanaged, this can lead to caloric surplus and fat gain rather than recomposition. Bedtime dosing helps by putting the peak hunger window during sleep.

Stacking MK-677 at 25 mg with ipamorelin or CJC-1295 for additional GH pulse stimulation is an advanced strategy some researchers use for maximum GH axis activation.

MK-677 Dosage for Anti-Aging

Here's where a lot of people over-engineer things. For anti-aging applications — GH restoration, sleep quality, skin thickness, cognitive sharpness — you don't need 25 mg. The 10–15 mg ibutamoren dosage range is fully sufficient.

This isn't just a guess. Nass et al. (2008) studied MK-677 in healthy elderly subjects over 12 months and found that even at relatively low doses, the compound restored IGF-1 to levels seen in younger adults without significant adverse effects — making it a viable option as explored in our sermorelin vs TRT vs MK-677 comparison. The whole anti-aging case for MK-677 is built on restoring age-related GH decline — not maximizing GH beyond physiological norms.

At 10–15 mg/day for anti-aging research, you can expect:

IGF-1 restoration toward youthful ranges (~40–55% increase from age-depleted baseline)
Improved slow-wave sleep within 1–2 weeks (see section below)
Skin hydration and thickness improvements over 8–12 weeks
Potential improvements in bone mineral density over longer cycles
Reduced hunger side effects compared to the 25 mg mk-677 dose

Older research subjects (50+) in particular tend to respond well at 10 mg because their baseline GH/IGF-1 is more depleted — the relative improvement is larger even at the lower dose. Pushing to 25 mg in this population increases insulin resistance risk without proportional benefit.

MK-677 Dosage for Sleep

Probably the most underappreciated application. At 10 mg taken before bed, MK-677 produces dramatic improvements in slow-wave (deep) sleep — typically within 1–2 weeks of starting the protocol. This isn't anecdotal. Murthy et al. documented significant increases in REM sleep and sleep quality markers in MK-677 research, consistent with ghrelin's known sleep-promoting effects at the hypothalamic level.

The mechanism makes sense: ghrelin receptor agonism promotes GH secretion, which is predominantly released during slow-wave sleep, and simultaneously amplifies the NREM sleep signal itself. You end up with more deep sleep and more GH output during that sleep — a compounding effect.

For sleep-focused research, the 10 mg mk-677 dosage is the practical recommendation (our peptide dosage calculator guide can help with conversions):

Take 30–60 minutes before bed
Effects on sleep quality are typically noticeable within the first week
Vivid dreams are commonly reported in weeks 1–2, usually settling by week 3
Going to 25 mg does not necessarily improve sleep further and significantly increases hunger at night

If the primary goal is sleep improvement, there's genuinely no reason to use more than 10 mg. Save the higher doses for when muscle growth or body recomposition is the target.

Morning vs Night Dosing

Morning vs Night Dosing: Which Is Better?

MK-677's ~24-hour half-life means once-daily dosing maintains consistent plasma levels and produces a sustained elevation in GH pulse amplitude and IGF-1. Splitting the dose is not required and provides no benefit over single daily dosing. But the timing still matters — and bedtime wins for most purposes.

Why bedtime dosing is optimal:

Aligns GH stimulation with the natural nocturnal GH pulse, potentially amplifying total nightly GH output
The hunger-stimulating effects of ghrelin receptor agonism are less disruptive during sleep — you're not awake fighting cravings
Synergizes with slow-wave sleep promotion for a compounding GH effect

When morning dosing makes sense:

When vivid dreams or sleep disturbance are a concern (occasional reports, especially in weeks 1–2)
When the research subject's schedule makes consistent bedtime dosing difficult
Morning dosing is compatible with fasted states post-waking, which may modestly enhance the GH pulse

ℹ️ Note: Unlike injectable GH secretagogues, the mk-677 dose does not require fasting for administration — it is active regardless of meal timing. However, the magnitude of the GH pulse may be modestly greater when taken fasted, consistent with ghrelin's known behavior. If bedtime dosing and hunger are both issues, try taking it right before sleep rather than 1–2 hours prior — the gap between dosing and waking is enough to blunt daytime appetite effects.

MK-677 Dosage Calculator

MK-677 Dosage Calculator — Worked Examples

You

How do I reconstitute Retatrutide 5mg with 2ml BAC water for 250mcg doses?

PeptideCoach

Add 2 mL BAC water to the 5 mg vial, swirl gently. Concentration = 2.5 mg/mL. For 250 µg, draw 0.1 mL (≈10 IU).

Reconstitution Calculator

How much to draw? Dosing schedule Side effects

Try our AI

Personalized protocols & interactive calculators

Try PeptideCoach

Top Pick BPC-157 5mg Research-grade BPC-157 — lyophilized, third-party tested, same-day US shipping. Exclusive 50% off — use code PEPTIDEDECK

Buy BPC-157 5mg

There's no official body-weight-based dosing protocol for MK-677 (unlike some peptides where mcg/kg matters significantly). Clinical trials used fixed doses — 10 mg, 25 mg, 50 mg — not weight-adjusted ones. That said, body size and composition do influence how people respond, particularly to the side effects.

Here's a practical framework for determining the right mk677 dosage for your research subject:

Start at 10 mg regardless of body weight

Week 1–2: 10 mg before bed. Assess hunger increase (scale of 1–10 compared to baseline) and any noticeable water retention or joint puffiness. Sleep quality changes are often apparent by day 4–7.

Decide at week 3 whether to increase

If hunger at 10 mg is manageable (5/10 or less) and the research goal is body recomposition or muscle growth, increase to 15 mg at week 3. If anti-aging or sleep is the goal, stay at 10 mg — it's sufficient.

Advance to 20–25 mg only if 15 mg is well-tolerated

If 15 mg shows acceptable side effects after 2 weeks, advance to 20–25 mg for the maximum muscle growth signal. Subjects over 90 kg who are highly active may tolerate 25 mg more readily than lighter subjects — not because of pharmacokinetics, but because the body composition goal warrants the hunger trade-off.

Example 1 — 70 kg male, body recomp goal: Start 10 mg weeks 1–2 → 15 mg weeks 3–4 → 20 mg week 5 onward. If hunger stays manageable at 20 mg, that's likely the ceiling. No need to push to 25 mg unless plateauing.

Example 2 — 80 kg male, maximum GH output goal: Start 10 mg weeks 1–2 → 15 mg weeks 3–4 → 25 mg week 5 onward. Manage hunger with bedtime dosing and disciplined diet structure.

Example 3 — 60 kg female, anti-aging / sleep: 10 mg, fixed dose, entire cycle. No escalation needed. The ibutamoren dosage at 10 mg is fully sufficient for these goals and keeps side effects minimal.

Cycle Length

MK-677 has the most robust clinical trial cycle length data of any GH secretagogue in research use:

Short cycle (8–12 weeks)

Sufficient for assessing changes in IGF-1, body composition, sleep quality, and recovery markers. An 8-week cycle at 25 mg/day is the standard structure for performance-focused research applications. A 4-week washout is typical.

Standard cycle (12–16 weeks)

The most common research framework. 16 weeks provides sufficient time for meaningful changes in lean mass, fat mass, and bone remodeling markers. A 4–8 week washout follows before re-initiation.

Extended / long-term research

Published clinical trials have studied MK-677 for up to 12 months (Nass et al., 2008) and even 2 years. These long-term studies provide important safety data but are not typical frameworks for general research. Long-term IGF-1 monitoring is essential in extended protocols, as sustained supraphysiological IGF-1 carries theoretical long-term risks.

Note on continuous vs. cycled use

Some research frameworks use a 5-days-on/2-days-off pattern or continuous dosing without cycling, arguing that MK-677's mechanism does not cause receptor desensitization at standard doses. However, extended continuous use warrants careful biomarker monitoring, and the published safety data beyond 2 years is limited.

MK-677 Long-Term Dosing

MK-677 Long-Term Dosing — Can You Use It Indefinitely?

This is one of the most common questions around the ibutamoren dosage literature, and the answer is nuanced. MK-677 is one of the few research compounds with published 2-year safety data in humans. The Nass et al. study ran for 12 months; other trials have extended further. Receptor desensitization — the main concern with many GH secretagogues — has not been clearly demonstrated with MK-677 at standard doses.

So in principle, longer-term use appears feasible. But that doesn't mean it's the recommended approach.

The concerns with truly continuous, indefinite use:

Sustained IGF-1 elevation: IGF-1 in the upper quartile of normal for extended periods is associated theoretically with increased proliferative risk. This hasn't been demonstrated definitively in MK-677 trials, but it's a monitoring consideration.
Insulin resistance: Chronic GH elevation reduces insulin sensitivity. Long-term use without breaks may cumulatively affect glucose metabolism, particularly in subjects with baseline metabolic risk.
Absence of washout data: We don't have good data on what happens after many years of continuous use. Prudence suggests cycling.

The practical recommendation: cycle 8–12 weeks on, 4–6 weeks off for most applications. If using for anti-aging over years, annual 8-week cycles are a reasonable model. The 2-year clinical data gives confidence that the compound isn't acutely dangerous long-term, but cycling still makes sense as standard practice.

Reconstitution & Preparation

MK-677 does not require reconstitution for most research preparations:

Oral capsules: Pre-measured doses (typically 10 mg or 25 mg per capsule). No preparation required. Store at room temperature away from moisture and heat.
Liquid solution: Often supplied at 25 mg/mL in a PEG-400 or DMSO/ethanol carrier. Use the provided dropper or micropipette to measure the dose. Shake well before use. Refrigerate after opening if directed by the supplier.
Raw powder: If weighing raw powder for research, use a precision milligram scale. MK-677 can be dissolved in DMSO, ethanol, or PEG-400 for solution preparation, or encapsulated. Stable as a powder at room temperature for extended periods if stored away from moisture.

Administration Guide

As an oral compound, MK-677 administration does not involve injection technique considerations. Key administration notes:

With or without food: The mk-677 dosage can be taken with or without food. Taking with a small meal may reduce GI discomfort at higher doses.
Avoid alcohol: Alcohol suppresses GH release and undermines the GH secretagogue effect. Evening alcohol consumption is particularly counterproductive in bedtime-dosed protocols.
Consistent daily timing: Due to the 24-hour half-life, dosing at approximately the same time each day maintains stable trough levels and avoids day-to-day variability in GH/IGF-1 data.
Dose titration in research: Starting at 10 mg/day for 1–2 weeks before advancing to 25 mg/day is a common titration approach to assess tolerance to hunger stimulation and water retention before committing to the standard research dose.

Stacking MK-677

MK-677's oral route and distinct ghrelin receptor mechanism make it compatible with injectable peptides that operate via different pathways:

MK-677 + Ipamorelin or CJC-1295: A hybrid GH stack combining oral and injectable secretagogues. MK-677 provides sustained IGF-1 elevation while ipamorelin/CJC-1295 produces additional discrete GH pulses. The combination produces significantly elevated total GH output and is used in advanced GH research. Ipamorelin is typically dosed on its standard schedule (200–300 mcg 1–2× daily) alongside MK-677's once-daily dose. See the Ipamorelin + CJC-1295 Stack Guide.
MK-677 + BPC-157: Used in recovery-focused research. MK-677 contributes the anabolic GH/IGF-1 signal; BPC-157 handles local tissue repair. No interaction expected between these independent mechanisms.
MK-677 + GHK-Cu: In anti-aging and skin health research models. GHK-Cu's collagen synthesis effects and MK-677's systemic GH/IGF-1 elevation provide complementary anabolic signals. See the GHK-Cu Guide.

Side Effects & Safety Considerations

MK-677 has the most characterized side effect profile of any GH secretagogue due to its clinical trial data. Researchers should be aware of the following dose-dependent effects:

Increased hunger/appetite: The most common and dose-dependent effect. MK-677 acts on ghrelin receptors, which regulate appetite, and increased hunger — especially at 25 mg and above — is reported by most research subjects. Particularly pronounced in the first 2–4 weeks. At the 10 mg mk-677 dose, hunger stimulation is typically manageable.
Water retention and edema: GH-mediated aldosterone effects lead to fluid retention, particularly in the extremities (hands, feet, face). Typically most pronounced in weeks 1–3 and partially resolves as the body adapts. More significant at 25 mg vs. 10 mg. High sodium intake exacerbates this.
Lethargy and fatigue: Some research subjects report increased fatigue, particularly at the 25–50 mg range. This may be related to the ghrelin-mediated sleep-promoting effects. Bedtime dosing often converts this from a side effect to a benefit (improved sleep quality).
Vivid dreams or sleep disturbance: Reported especially at higher doses or when dosing in the evening. Usually resolves after 2–3 weeks. Switching to morning dosing can mitigate this.
Mild numbness or tingling: Reported in clinical trials, particularly in extremities. Thought to be carpal tunnel-related fluid retention rather than a direct neurotoxic effect.
Transient insulin resistance: MK-677 can transiently raise fasting blood glucose, particularly at higher mk-677 doses. Published clinical trials document modest increases in fasting glucose and insulin levels. This is a key monitoring parameter in diabetic or metabolic research models.
IGF-1 elevation: Consistent and dose-dependent. At 25 mg/day, IGF-1 typically increases 60–80% above baseline. Long-term implications of sustained IGF-1 elevation require monitoring.
No impact on cortisol or prolactin: Unlike some GHRPs, MK-677 does not significantly raise cortisol or prolactin in published clinical studies at 25 mg/day.

What Happens If You Take Too Much MK-677?

Taking too much MK-677 isn't acutely dangerous in the way that overdosing on many research compounds can be. But it's genuinely unpleasant, and the side effects scale predictably with the mk-677 dosage.

Above 25 mg/day, and especially at 50 mg+:

Hunger becomes overwhelming. At 50 mg, appetite stimulation is severe enough that caloric intake can skyrocket. This actively works against body recomposition goals. The ghrelin receptor agonism at that dose is far beyond what the body's normal hunger regulation can compensate for.
Water retention is significant. Visible puffiness, particularly in the hands, face, and ankles. Joint discomfort from fluid pressure, especially carpal tunnel-type symptoms in the wrists.
Insulin resistance increases meaningfully. As covered in our MK-677 safety guide, at high doses, fasting glucose elevation can move outside normal ranges, particularly in subjects with existing metabolic sensitivity. This is the most clinically relevant risk of over-dosing.
Fatigue and cognitive fog. High-dose ghrelin agonism promotes excessive sedation. Not dangerous, but counterproductive.

⚠️ Note: There's no evidence that exceeding the 25 mg mk677 dosage provides additional IGF-1 benefit — clinical data shows diminishing returns above 25 mg with a sharp increase in side effects. The 25 mg dose is essentially the ceiling of the therapeutic window for most research applications. Going higher trades benefit for burden.

FAQs

Frequently Asked Questions

Is MK-677 the same as a peptide?

No. MK-677 is a non-peptide small molecule GH secretagogue that mimics the action of ghrelin (a peptide) at the GHS-R1a receptor. It is often grouped with research peptides due to its shared GH-stimulating function and research context, but structurally and pharmacologically it is a distinct compound. Its key advantage over peptide GHRPs is oral bioavailability — it does not require injection.

How much does MK-677 raise IGF-1?

In published clinical trials, 25 mg/day of MK-677 increased IGF-1 levels by approximately 60–79% above baseline over 12 months. At the 10 mg mk-677 dosage, increases of 40–52% are documented. These are among the most precisely characterized IGF-1 effects of any GH secretagogue in the research literature.

Does MK-677 require cycling or can it be taken continuously?

Published clinical trials have used MK-677 continuously for up to 12–24 months without clear evidence of receptor desensitization. However, most research frameworks still employ cycling (8–16 weeks on, 4–8 weeks off) to assess recovery of baseline parameters and limit cumulative IGF-1 exposure. Truly continuous long-term use requires ongoing IGF-1, glucose, and insulin monitoring.

Why does MK-677 cause so much hunger?

MK-677 agonizes the ghrelin receptor (GHS-R1a), and ghrelin is the primary orexigenic (appetite-stimulating) hormone in the body. This hunger stimulation is an on-target, mechanism-driven effect — not an off-target side effect. It tends to diminish after the first 2–4 weeks as the body adapts. The 10 mg ibutamoren dosage significantly reduces this effect compared to 25 mg while preserving most of the IGF-1 benefit.

Does MK-677 affect blood sugar?

Yes — MK-677 can transiently increase fasting blood glucose and reduce insulin sensitivity, particularly at higher mk-677 doses. Clinical trials document modest increases in fasting glucose, though these remained within normal ranges in healthy subjects at 25 mg/day. Research protocols in diabetic or insulin-resistant models should monitor glucose and insulin closely.

Can MK-677 be stacked with injectable GH secretagogues?

Yes. Because MK-677 acts at the ghrelin receptor while injectable peptides like CJC-1295 act at GHRH receptors and ipamorelin acts at GHS-R1a, combinations can produce additive or synergistic GH output. However, stacking all three significantly increases total GH and IGF-1 elevation, requiring careful monitoring. This approach is used in advanced GH axis research protocols.

Is MK-677 legal to purchase for research?

MK-677's legal status varies by country. In the US, it is not FDA-approved and is not a scheduled substance; it is sold legally as a research chemical not for human consumption. It is banned by WADA for competitive athletes. Researchers should verify applicable local regulations and choose a reputable peptide source before procurement.

Can I take MK-677 with food?

Yes, the mk-677 dose can be taken with or without food. Unlike some compounds where fasted administration is critical, MK-677 is active regardless of meal timing. Taking it with a small meal may reduce nausea at higher doses. The one nuance: the GH pulse response may be modestly greater when taken fasted, but the practical difference is small.

Can you take MK-677 every day?

Yes. MK-677's 24-hour half-life makes once-daily, every-day dosing the standard protocol. There's no evidence that taking days off improves efficacy or recovery. Some frameworks use 5-days-on/2-days-off, but this is not based on pharmacological necessity — it's more of a personal preference. Daily dosing at consistent times is the cleaner approach for maintaining steady IGF-1 levels.

What is the right MK-677 dosage for someone over 50?

For older research subjects (50+), the 10 mg ibutamoren dosage is the starting point and often the final dose. Baseline GH and IGF-1 are typically lower in this population, meaning the relative response at 10 mg is actually larger than in younger subjects. The clinical trial by Nass et al. studied exactly this population and found meaningful results at low doses with a favorable safety profile. Insulin sensitivity is also a greater concern in older subjects, making the 25 mg mk-677 dose harder to justify without monitoring.

Can you split the MK-677 dose?

You can, but there's no good reason to. MK-677's 24-hour half-life means once-daily dosing already maintains stable plasma levels around the clock. Splitting a 25 mg dose into 12.5 mg twice daily doesn't improve efficacy and complicates the protocol unnecessarily. It also means one dose is likely landing during the day when hunger side effects are harder to manage. Single bedtime dosing is the cleaner approach.

What is the recommended MK-677 dosage for a first cycle?

For a first cycle, 10 mg/day for the full 8–12 weeks is the recommended mk677 dosage. Many first-time users underestimate the hunger side effect — starting at 10 mg gives you a real sense of how ghrelin receptor agonism feels before committing to 25 mg. If 10 mg tolerance is good after 3–4 weeks and the goal demands it, stepping up to 15–20 mg is reasonable. Skipping straight to 25 mg on a first cycle is a common mistake that leads people to quit due to unmanageable appetite.

📚 References

Nass R et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial." Ann Intern Med. 2008;149(9):601-611. PubMed
Murphy MG et al. "MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism." J Clin Endocrinol Metab. 1998;83(2):320-325. PubMed
Chapman IM et al. "Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects." J Clin Endocrinol Metab. 1996;81(12):4249-4257. PubMed
Copinschi G et al. "Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles." J Clin Endocrinol Metab. 1996;81(8):2776-2782. PubMed
Svensson J et al. "Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure." J Clin Endocrinol Metab. 1998;83(2):362-369. PubMed
Murphy MG et al. "Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women." J Clin Endocrinol Metab. 2001;86(3):1116-1125. PubMed

⚠️ Medical Disclaimer:

This article is intended for informational and research purposes only. MK-677 (ibutamoren) is a research compound and is not approved by the FDA or any equivalent regulatory body for human use, diagnosis, treatment, or prevention of any medical condition. While clinical trial data exists for MK-677, this information does not constitute medical advice or a recommendation for human self-administration. Consult a qualified healthcare professional before considering any research compound use.